Usefulness of sustained-release diltiazem for stable angina pectoris

The American Journal of Cardiology
W P KlinkeE E Dempsey

Abstract

Sustained-release diltiazem, 120 and 180 mg twice daily, was assessed in a multicenter, double-blind, randomized, placebo-controlled trial in 65 stable angina patients with exercise-induced ST depression. Exercise testing was performed 12 +/- 1 hours after the last dose at the end of each of the 3 treatment weeks. Both dose levels of drug reduced spontaneous angina (p less than 0.001) and increased exercise duration (p less than 0.01) and time to 1-mm ST depression (p less than 0.001). No differences were noted between the 2 dose levels. Rate-pressure product at maximal exercise was similar for the 3 groups. Only 1 patient terminated the study because of adverse drug effects; severe adverse effects occurred in 1 placebo and 1 low-dose period. Sustained-release diltiazem is safe and efficacious monotherapy for patients with stable angina.

References

Jan 1, 1986·The American Journal of Cardiology·D A WeinerM D Klein
Dec 1, 1983·Journal of the American College of Cardiology·B S LindenbergM D Klein
Sep 1, 1984·The American Journal of Cardiology·M J O'HaraE B Raftery
Apr 1, 1983·Journal of the American College of Cardiology·V Bala SubramanianE B Raftery
Feb 18, 1982·The American Journal of Cardiology·K F HossackT A Ports

❮ Previous
Next ❯

Citations

Mar 15, 1995·The American Journal of Cardiology·C NadeauL Larivière
Oct 30, 1998·Fundamental & Clinical Pharmacology·M G HendriksJ H Jonkman
Jul 1, 1993·International Journal of Cardiology·R SteffensenS Haunsø

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.